March 21, 2025 – Talk Bio

Johnson & Johnson Announces $55 Billion Investment in U.S. Manufacturing and Innovation

1 month ago talkbio0Tagged aligns, announcement, Benefit, capabilities, commitment, Corporation, domestic pharmaceutical industry, Increased, innovation, Investments, J&J 's, Manufacturing, Surgical construction, trends qualifier, United States

This major investment demonstrates J&J’s commitment to expanding its U.S. manufacturing and innovation capabilities, with potential benefits for job creation and the domestic pharmaceutical industry. The announcement aligns with broader trends of increased U.S. manufacturing investment by large corporations in recent years.

AstraZeneca details $2.5B investment in China’s political center, funding R&D center, biotech pacts

1 month ago talkbio0Tagged AstraZeneca, Beijing, China, China 's, Collaboration, Investments

Investments, AstraZeneca, Beijing, China, China ‘s, Collaboration

J&J advances Stelara succession scheme with FDA nod for Tremfya in Crohn’s disease

1 month ago talkbio0Tagged Approved, CD, Crohn 's disease, J&J 's, Tremfya, United States Food and Drug Administration

Tremfya, United States Food and Drug Administration, Crohn ‘s disease, Approved, CD, J&J ‘s

Novartis snags FDA nod for Fabhalta in another kidney disease but leaves room for rival Apellis

1 month ago talkbio0Tagged Apellis, Approved, C3 G, Fabhalta, Kidney Diseases, Novartis, pegcetacoplan, Proteinuria, United States Food and Drug Administration

Fabhalta, United States Food and Drug Administration, Apellis, Novartis, Approved, C3 G, Proteinuria, pegcetacoplan, Kidney Diseases

Alnylam’s Amvuttra Approved for ATTR Cardiomyopathy, Challenging Pfizer and BridgeBio

1 month ago talkbio0Tagged Amvuttra, Approved, ATTR-CM, Cardiomyopathies, RNA Interference, United States Food and Drug Administration

Amvuttra, vutrisiran, ATTR-CM, FDA approval, RNAi therapeutic, cardiomyopathy

A closer look at pharmas top patent losses in 2025

1 month ago talkbio0Tagged 2023, 2025, Bayer, competition, Expiration, function, Impact food supplement, Indication of (contextual qualifier), Legal patent, Market, Patent Cliff, Regeneron, Sales - occupational activity

Legal patent, Expiration, function, Market, Indication of (contextual qualifier), competition, Impact food supplement, Sales – occupational activity, Bayer, 2025, patent cliff, Regeneron, 2023